UnicoCell Biomed Co., Ltd. (TPEX: 6794) announced today that its exosome products have received Notification of Cosmetic Product from the Philippine Food and Drug Administration, enabling commercial distribution in the Philippines. The approval marks the company's expansion into Southeast Asia following its successful commercialization in Japan.
The Philippines, with a population exceeding 100 million, represents a rapidly growing market for aesthetic and cosmetic products in Southeast Asia. This notification confirms that the products meet ASEAN Cosmetic Directive standards, a regulatory framework shared across ten member states. Meeting these standards may streamline UnicoCell's regulatory filings in other ASEAN markets. UnicoCell will work with local partners to develop the Philippine market and pursue product registrations in additional ASEAN countries.
UnicoCell has established a comprehensive international regulatory and certification framework in the exosome field, with its technical capabilities recognized across multiple markets. Its stem cell secretome exosome ingredient holds U.S. FDA Drug Master File (MF) registration, demonstrating pharmaceutical-grade manufacturing and quality standards. The ingredient has also received multiple International Nomenclature of Cosmetic Ingredients (INCI) designations, enabling use in cosmetic formulations worldwide.
UnicoCell's patented manufacturing process enhances exosome concentration, purity, and scalability. In 2024, this technology received the Bronze Award in Manufacturing Technology at Taiwan's National Biotechnology Research Park Awards—the only exosome production process to earn this recognition. UnicoCell exosome ingredients are currently marketed in Japan and now authorized for sale in the Philippines.
Alongside its core drug development pipeline, UnicoCell continues to advance exosome product commercialization across Asian markets, demonstrating a diversified commercialization strategy.
Contact: Ray Liu
Phone: 886-2-27922699
Mail: info@unicocell.com